| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2005 | US20050158350 Use of licochalcone a or of an extract of radix glycyrrhizae inflatae that contains licochalcone a against postinflammatory hyperpigmentation |
| 07/21/2005 | US20050158348 Eutectic mixture of camphor, menthol, thymol and similar compounds is a powerful solvent for non-steroidal anti-inflammatory drugs; transdermal drug delivery of e.g. indomethacin, diclofenac, or ketoprofen |
| 07/21/2005 | US20050158337 Rehydrating personal lubricant and method of use |
| 07/21/2005 | US20050158329 Novel phytol derived immunoadjuvants and their use in vaccine formulations |
| 07/21/2005 | US20050158325 Comprises imidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, oxazolonaphthyridine amine, or thiazolonaphthyridine amine derivatives |
| 07/21/2005 | US20050158321 Drug screening; for methotrexate resistant patients |
| 07/21/2005 | US20050158320 Combinations for the treatment of proliferative diseases |
| 07/21/2005 | US20050158317 Novel proteins with il-6 inhibiting activity |
| 07/21/2005 | US20050158310 Via modulating insulin receptor signaling in adipocyte tissue; transgenic/knockout animal; RNA interference |
| 07/21/2005 | US20050158291 Pet food composition for skin photoprotection |
| 07/21/2005 | US20050158290 Process for the preparation of a nutrient formulation |
| 07/21/2005 | US20050158288 Methods of organ regeneration |
| 07/21/2005 | US20050158281 vascular permeability agents (VPAs), such as VEGF, used in conjunction with adeno-associated virus(AVV) a nucleic acid viral vectors; nucleic cid sequences encoding Igf-1( insulin like growth factor-1) and dystrophin or dystrophin-like proteins; muscular disorders |
| 07/21/2005 | US20050158276 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host |
| 07/21/2005 | US20050158274 Therapeutic use of a fibrosing agent to induces a fibrotic response at a specific site, thereby providing the patient with pulmonary sealing |
| 07/21/2005 | US20050158272 Depositing a liquid embolic composition of polyethylene glycol diacrylate (PEGDA), pentaerythritol tetra(3-mercaptopropionate), in a buffer into a lumen; curing by cross-linking or polymerization |
| 07/21/2005 | US20050158264 Sympathetic nerve-stimulating fragrant compositions |
| 07/21/2005 | US20050158263 Pyrithione biocides enhanced by zinc metal ions and organic amines |
| 07/21/2005 | US20050158258 Cosmetic blend of ximenynic acid, niacin, alpha-lipoic acid, or a mushroom extract; anti aging |
| 07/21/2005 | US20050158255 Use of benzotriazole UV absorbers |
| 07/21/2005 | US20050158253 Enzyme and an enzyme-anchor complex; degrades biofilm structures; complex acts as a bactericide |
| 07/21/2005 | US20050158251 Oral composition of solvent, an oxidant and alkyl cellulose in varnish form |
| 07/21/2005 | US20050158249 Therapeutic, prophylactic or diagnostic agent and biodegradable polymer; deposited after the first bifurcation of the lungs |
| 07/21/2005 | US20050158239 Perturbed membrane-binding compounds and methods of using the same |
| 07/21/2005 | DE20221251U1 Intelligentes, serielles Batterieladegerät und Ladeblock Intelligent, serial battery charger and charging block |
| 07/21/2005 | DE19901683B4 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/21/2005 | DE10360835A1 New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| 07/21/2005 | DE10360154A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia |
| 07/21/2005 | DE10359829A1 Verwendung von CHP als Inhibitor von Glutathion-S-Transferasen und Kollagen IV Use of CHP as an inhibitor of glutathione-S-transferases, and collagen IV |
| 07/21/2005 | DE10359798A1 Cyclohexadepsipeptide zur Bekämpfung von Endoparasiten und ein Verfahren zu ihrer Herstellung Cyclohexadepsipeptides for controlling endoparasites and a method for their preparation |
| 07/21/2005 | DE10359790A1 Brausezubereitung einer basischen arzneilich wirksamen Substanz Effervescent formulation of a basic biological active substance |
| 07/21/2005 | DE10358814A1 Prolinylarylacetamide Prolinylarylacetamide |
| 07/21/2005 | DE10356187A1 Wirkstoffkombinationen aus Phytosterolen und/oder Cholesterin und Licochalcon A oder einem wäßrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A Active compound combinations of phytosterols and / or cholesterol and licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae containing licochalcone A |
| 07/21/2005 | DE10024383B4 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells |
| 07/21/2005 | CA2678165A1 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| 07/21/2005 | CA2678125A1 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| 07/21/2005 | CA2678124A1 Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride |
| 07/21/2005 | CA2592891A1 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation |
| 07/21/2005 | CA2592867A1 Treatment |
| 07/21/2005 | CA2592631A1 Compositions and methods to treat recurrent medical conditions |
| 07/21/2005 | CA2553211A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer |
| 07/21/2005 | CA2552946A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | CA2552909A1 Pharmaceuticals for topical application in animals |
| 07/21/2005 | CA2552851A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | CA2552850A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | CA2552739A1 Cysteine protease inhibitors |
| 07/21/2005 | CA2552726A1 Cathepsin cysteine protease inhibitors |
| 07/21/2005 | CA2552641A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 07/21/2005 | CA2552632A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer |
| 07/21/2005 | CA2552630A1 Non-disintegrating oral solid composition of high dose of water soluble drugs |
| 07/21/2005 | CA2552627A1 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent |
| 07/21/2005 | CA2552483A1 Use of idebenone for the preparation of a topically-applied depigmentation composition and corresponding composition |
| 07/21/2005 | CA2552440A1 Pharmaceutical composition |
| 07/21/2005 | CA2552411A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata |
| 07/21/2005 | CA2552221A1 Donepezil formulations |
| 07/21/2005 | CA2552126A1 Ziprasidone formulations |
| 07/21/2005 | CA2552114A1 Solid dosage formulations of galantamine |
| 07/21/2005 | CA2552101A1 Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds |
| 07/21/2005 | CA2552098A1 Benzo[d]isoxazol-3-ol daao inhibitors |
| 07/21/2005 | CA2552090A1 Disubstituted chalcone oximes as selective agonists of rar.gamma. retinoid receptors |
| 07/21/2005 | CA2552064A1 Atomoxetine formulations |
| 07/21/2005 | CA2551952A1 Pyrrole and pyrazole daao inhibitors |
| 07/21/2005 | CA2551946A1 Immediate, controlled and sustained release formulations of galantamine |
| 07/21/2005 | CA2551900A1 Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors |
| 07/21/2005 | CA2551862A1 Piperazines useful for treating pain |
| 07/21/2005 | CA2551826A1 Inhalant formulation containing sulfoalkyl ether .gamma.-cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551815A1 Novel drug compositions and dosage forms |
| 07/21/2005 | CA2551749A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 07/21/2005 | CA2551528A1 Enteric coated aliphatic amine polymer bile acid sequestrants |
| 07/21/2005 | CA2551525A1 Pharmaceutical composition for thrombin peptide derivatives |
| 07/21/2005 | CA2551524A1 Treatment of malignant gliomas with tgf-beta inhibitors |
| 07/21/2005 | CA2551523A1 Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever |
| 07/21/2005 | CA2551520A1 Immunomodulatory compounds for the treatment of central nervous system disorders |
| 07/21/2005 | CA2551518A1 Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
| 07/21/2005 | CA2551399A1 Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
| 07/21/2005 | CA2551346A1 N-substituted piperidine and piperazine derivatives |
| 07/21/2005 | CA2551294A1 Disubstituted chalcone oximes having rary retinoid receptor antagonist activity |
| 07/21/2005 | CA2550873A1 Inhibitors of methionine aminopeptidase-2 and uses thereof |
| 07/21/2005 | CA2550854A1 Membranes incorporating recognition moieties |
| 07/21/2005 | CA2550717A1 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| 07/21/2005 | CA2550709A1 Preventive for the onset of liver cancer comprising quinone compound as the active ingredient |
| 07/21/2005 | CA2550699A1 Novel drug compositions and dosage forms of topiramate |
| 07/21/2005 | CA2550642A1 Oligonucleotide compound and method for treating nidovirus infections |
| 07/21/2005 | CA2550515A1 Protease inhibitors |
| 07/21/2005 | CA2550504A1 Treatment of skin using a benefit agent and an apparatus |
| 07/21/2005 | CA2550189A1 Thiadiazoles as cxc- and cc- chemokine receptor ligands |
| 07/21/2005 | CA2550186A1 Antiaging composition |
| 07/21/2005 | CA2549979A1 3-quinuclidinyl heteroatom bridged biaryl derivatives |
| 07/21/2005 | CA2549976A1 3-quinuclidinyl amino-substituted biaryl derivatives |
| 07/21/2005 | CA2549962A1 Spirocyclic quinuclidinic ether derivatives |
| 07/21/2005 | CA2549731A1 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 07/21/2005 | CA2549641A1 Mitotic kinesin inhibitors |
| 07/21/2005 | CA2549396A1 Cb1 modulator compounds |
| 07/21/2005 | CA2549385A1 Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes |
| 07/21/2005 | CA2549330A1 Calcitonin gene related peptide receptor antagonists |
| 07/21/2005 | CA2549089A1 Opioid receptor antagonists |
| 07/21/2005 | CA2548849A1 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/21/2005 | CA2548671A1 Compositions for treating or preventing obesity and insulin resistance disorders |
| 07/21/2005 | CA2548179A1 Methods and compositions for the production of monoclonal antibodies |
| 07/21/2005 | CA2548039A1 5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |